Company Filing History:
Years Active: 2003
Title: Ingun Tryland: Innovator in Rapid Coliform Detection
Introduction
Ingun Tryland is a notable inventor based in Oslo, Norway. He has made significant contributions to the field of microbiology, particularly in the detection of coliform bacteria in dairy products. His innovative approach has the potential to enhance food safety and quality assurance in the dairy industry.
Latest Patents
Ingun Tryland holds a patent for a "Rapid coliform detection system." This invention provides a rapid method for detecting the presence or absence of coliform bacteria in liquid or liquified dairy samples, such as skimmed milk, low-fat milk, or whole milk. The process involves combining a growth medium containing a fluorogenic substrate with the dairy sample and incubating it for a brief period, typically around four hours. After this initial incubation, a first fluorescence value of 4-methylumbelliferone is measured. The sample is then incubated again for an additional 2-8 hours, after which a second fluorescence value is measured. The presence of total, fecal, or thermotolerant coliform bacteria is determined if the second fluorescent value exceeds the first by a predetermined concentration threshold of 4-methylumbelliferone.
Career Highlights
Ingun Tryland is associated with Nye Colifast AS, a company dedicated to developing innovative solutions for microbiological testing. His work has been instrumental in advancing rapid testing methods that are crucial for ensuring the safety of dairy products.
Collaborations
Ingun collaborates with talented individuals such as James D. Berg and Kari Skjanes, who contribute to the research and development efforts at Nye Colifast AS. Their combined expertise enhances the effectiveness of the innovations being developed.
Conclusion
Ingun Tryland's contributions to the field of rapid coliform detection represent a significant advancement in food safety technology. His innovative methods are poised to make a lasting impact on the dairy industry and beyond.